{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-007182","form_type":"8-K/A","ticker":null,"cik":"0001506928","company_name":"Avinger Inc","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.380185+00:00","generated_at":"2026-06-05T00:30:02.708101+00:00","sec_items":["3.03","1.01","5.03","2.03","3.02","5.02","5.07","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Avinger enters strategic partnership with Zylox-Tonbridge; receives $7.5M initial investment","bullets":["License Agreement for Avinger products in Greater China; 20-year initial term, mid-single to high-single digit royalty.","Collaboration Agreement gives Avinger option to distribute Zylox-Tonbridge peripheral products in U.S. and Germany.","Purchaser invested $7.5M for common shares and Series F preferred; potential $7.5M more on Milestones (FDA registration, $10M revenue).","Jonathon Zhong Zhao appointed to Board as Class II director.","Loan Amendment with CRG extends interest-only period to Dec 2026; interest may be paid in kind."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-007182","json":"https://secwatch.observer/filing/0001437749-24-007182.json","markdown":"https://secwatch.observer/filing/0001437749-24-007182.md","text":"https://secwatch.observer/filing/0001437749-24-007182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924007182/0001437749-24-007182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924007182/avgr20240308_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:30:02.708101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c86cc0032d","claim":"Jonathon Zhong Zhao was appointed as Class II Director at Avinger Inc.","evidence_excerpt":"Jonathon Zhong Zhao was appointed to serve as a Class II member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924007182/0001437749-24-007182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"125e80f5fc2a1779aac8fd4b9616eda082338eaa","claim":"Avinger Inc: Filed amendment to Series E Convertible Preferred Stock certificate reducing beneficial ownership limitation (effective 2024-03-04).","evidence_excerpt":"on March 4, 2024, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (the “Series E Amendment”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924007182/0001437749-24-007182-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-04"}],"fact_type":"governance_change"},{"claim_id":"47e8d488f891c8671b6118959826328b78a0337e","claim":"Avinger Inc: Filed Certificate of Designation of Series F Preferred Stock (effective 2024-03-04).","evidence_excerpt":"on March 4, 2024, the Company filed the Series F Certificate of Designation, designating 7,224 shares of Series F Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924007182/0001437749-24-007182-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-04"}],"fact_type":"governance_change"},{"claim_id":"7957927a08bb84f4a4a5dd509e5c20d467fc0415","claim":"Avinger Inc: Filed Certificate of Designation of Series A-1 Preferred Stock (effective 2024-03-04).","evidence_excerpt":"on March 4, 2024, the Company filed the Series A-1 Certificate of Designation, designating shares of Series A-1 Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924007182/0001437749-24-007182-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-04"}],"fact_type":"governance_change"},{"claim_id":"5ff00faf9fc9a1d26cd6834fb8f645d7b025ef54","claim":"Avinger Inc entered into Securities Purchase Agreement with Zylox-Tonbridge Medical Limited valued at $15 million (effective 2024-03-04).","evidence_excerpt":"the Company and Zylox-Tonbridge Medical Limited, a wholly-owned subsidiary of Zylox-Tonbridge (the “Purchaser”), entered into a Securities Purchase Agreement (the “Purchase Agreement”), pursuant to which the Purchaser agreed to purchase, in two tranches, up to an aggregate of $15 million in shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924007182/0001437749-24-007182-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Zylox-Tonbridge Medical Limited"},{"label":"Value","value":"$15 million"},{"label":"Effective","value":"2024-03-04"}],"fact_type":"material_agreement"},{"claim_id":"76929662442191680dce2377ca3d742b144a1488","claim":"Avinger Inc entered into License and Distribution Agreement with Zylox-Tonbridge Medical Technology Co., Ltd. (effective 2024-03-04).","evidence_excerpt":"On March 4, 2024, Avinger, Inc. (“Avinger” or the “Company”) entered into a License and Distribution Agreement (the “License Agreement”) with Zylox-Tonbridge Medical Technology Co., Ltd. (“Zylox-Tonbridge”) effective as of the Initial Closing (defined below)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924007182/0001437749-24-007182-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Zylox-Tonbridge Medical Technology Co., Ltd."},{"label":"Effective","value":"2024-03-04"}],"fact_type":"material_agreement"},{"claim_id":"e2740af643695dee16a71af3b06d4c60ede1e125","claim":"Avinger Inc entered into Strategic Cooperation and Framework Agreement with Zylox-Tonbridge Medical Technology Co., Ltd. (effective 2024-03-04).","evidence_excerpt":"on March 4, 2024, the Company and Zylox-Tonbridge also entered into a Strategic Cooperation and Framework Agreement in conjunction with the Initial Closing (the “Collaboration Agreement”","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924007182/0001437749-24-007182-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Zylox-Tonbridge Medical Technology Co., Ltd."},{"label":"Effective","value":"2024-03-04"}],"fact_type":"material_agreement"},{"claim_id":"6ca66c180427d342ed499e292651bc63b4e1ca28","claim":"Avinger Inc shareholders approved Approval of License Agreement, Purchase Agreement, and related transactions at the 2024-03-04 meeting.","evidence_excerpt":"On March 4, 2024, the holders of all of the outstanding shares of the Series A Preferred Stock and Series E Preferred Stock approved the License Agreement, the Purchase Agreement, and the transactions contemplated thereby, including the amendment, the issuance of the Series F Preferred Stock and Series G Preferred stock, the Exchange, and the Series E Amendment, by written consent.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506928/000143774924007182/0001437749-24-007182-index.htm","confidence":0.4,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-03-04"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}